Bio-Techne CorpTECH
Price$72.40Intrinsic value$52.2028% below price

Valuation

How Intrinsic Value compares with model outputs

Intrinsic Value $52.20median of 6 methods · middle span $24-$73based on filings through 31 Mar 2026
Market Price $72.40Price as of 1 Oct 2026
Margin of Safety -27.9%as of 1 Oct 2026

Valuation methods vs. Market Price

Company vs. peer median Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions

ParameterValue
Years 1–5: analyst growth pathFive-year total matches analyst consensus exactly. Year 1: -6.2% (near-term consensus, capped) · years 2–5: 16.5%/yr (balance of the path).11.6% per year
Years 6–10: glide to demonstrated growth own history 33.4%, capped at 20%
Per-year rates
Yr 615.5%Yr 714.5%Yr 813.5%Yr 912.6%Yr 1011.6%
16.5% → 11.6%
Years 11–20: glide to long-run rate
Per-year rates
Yr 1110.7%Yr 129.8%Yr 139.0%Yr 148.1%Yr 157.3%Yr 166.4%Yr 175.6%Yr 184.7%Yr 193.9%Yr 203.0%
11.6% → 3.0%
Beyond year 20: terminal growthPerpetual long-run rate3.0%
Historical EPS growth (multi-year median)median of 3 windows (5/6/7y)33.4%
Discount rate (cost of equity) 10.3%
Volatility vs market (adjusted beta)1.19

Valuation Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions Sandbox Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Compare with peers

Search any company to compare valuation, profitability, returns, growth, and financial strength side by side.

Compare the target company plus 1 peer. Sign in / Sign up to compare a maximum of 3 peers.

Best in rowHigher is betterLower is better—Data not available
TargetBio-Techne CorpTECHHealth Care
Valuation
P/E62.4×
P/S9.4×
P/B5.4×
EV / Revenue9.3×
EV / EBITDA30.7×
Profitability
Gross margin64.8%
Operating margin8.4%
Net margin9.0%
FCF margin21.7%
Returns
ROE5.2%
ROA4.2%
ROIC5.4%
Growth
Revenue growth (YoY)-0.4%
5-yr fwd EPS growth11.6%
Financial strength
Debt / Equity0.09×
Current ratio4.55×
Altman Z-Score16.4
Interest coverage—
Dividend yield0.6%

Best value in each row is highlighted. Figures are periodic snapshots from the same filings used across each dossier; a dash means the figure is not available.

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.